Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Moleculin Biotech ( (MBRX) ) just unveiled an announcement.
On December 9, 2025, Moleculin Biotech announced an update on its pivotal Phase 2B/3 MIRACLE study of Annamycin for treating relapsed or refractory acute myeloid leukemia (AML). The enrollment has increased to 78% of the target for the first interim unblinding, with completion expected in the first quarter of 2026. This progress supports the potential of Annamycin to address a significant gap in AML treatment, with the trial expanding across seven countries. The company aims to complete Part A of the trial with 90 subjects by mid-2026, as they continue to recruit and analyze data to determine the best dosage for further trials.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Their lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, aiming to overcome multidrug resistance and reduce cardiotoxicity.
Average Trading Volume: 151,670
Technical Sentiment Signal: Sell
Current Market Cap: $14.96M
See more data about MBRX stock on TipRanks’ Stock Analysis page.